Beloo Mirakhur
Plex Pharmaceuticals (United States)(US)Astex Pharmaceuticals
Publications by Year
Research Areas
Neuroendocrine Tumor Research Advances, Neuroblastoma Research and Treatments, Pancreatic and Hepatic Oncology Research, Lung Cancer Research Studies, Pituitary Gland Disorders and Treatments
Most-Cited Works
- → Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial(2012)2,954 cited
- → Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose(2008)1,467 cited
- → NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors(2019)309 cited
- → MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy(2009)174 cited
- → High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses.(1990)147 cited
- → An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).(2013)111 cited
- → Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody(2002)67 cited
- → Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine(2014)54 cited
- → A desensitization protocol for the mAb cetuximab(2008)44 cited
- → Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma(2015)43 cited